Novartis Moves on Three Strategic Fronts with Acquisition, IgAN Data, and Access Expansion
Image
SHERIDAN, WYOMING - April 14, 2026 - Novartis AG has released three material press items in under three weeks, reflecting concurrent execution across corporate development, clinical pipeline, and market access. The Basel-headquartered pharmaceutical company agreed on March 27 to acquire Excellergy, Inc., adding a next-generation anti-IgE candidate to its immunology portfolio; published positive IgA nephropathy outcomes data in a peer-reviewed journal on March 29; and on April 9 announced a structured community health expansion targeting more than 30 countries by 2030. The company's medicines currently reach 296 million patients worldwide, a baseline against which the scope of these moves carries direct commercial and operational weight.